Cystic fibrosis colonopathy.

Area of Science:

• Gastroenterology
• Pediatric Gastroenterology
• Clinical Pathology

Background:

• A novel disease, fibrosing colonopathy, emerged in 1994, associated with excessive pancreatic enzyme administration.
• Over 60 worldwide cases were documented prior to the implementation of enzyme dosage guidelines.
• Predisposing factors included young age, prior intestinal surgery, meconium ileus equivalent, and concurrent use of H2 blockers, corticosteroids, and DNase.

Purpose of the Study:

• To describe the clinical and pathological features of fibrosing colonopathy.
• To identify predisposing factors and associated conditions.
• To differentiate fibrosing colonopathy from other intestinal diseases.

Main Methods:

• Review of clinical case data.
• Analysis of pathological findings from affected patients.
• Comparison with features of Crohn's disease and ischemic bowel disease.

Main Results:

• Abnormal findings included foreshortened colon, strictures, submucosal fibrosis, ascites, and liver nodular hyperplasia.
• Histologic examination revealed eosinophilia, mild cryptitis, epithelial regeneration, and muscularis mucosa disruption.
• The condition's features are distinct from, yet share similarities with, Crohn's disease and ischemic bowel disease.

Conclusions:

• Fibrosing colonopathy is a distinct clinicopathological entity linked to pancreatic enzyme therapy.
• The precise pathogenic mechanisms underlying fibrosing colonopathy remain to be elucidated.
• Understanding these features is crucial for differentiating it from other bowel pathologies.